MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy

<p><span style="font-weight: 400;">FDA pull bebtelovimab; compounding guidance issued in light of the amoxicillin shortage; the first fecal microbiota treatment is approved; a treatment for Alzheimer disease agitation shows promise; and a gene therapy for duchenne muscular dystrophy is accepted for Priority Review.</span></p>